Eric Adam Joins HAYA Therapeutics as Chief Operating Officer

Share This Post

Key Highlights

  • Eric Adam, Ph.D., appointed as COO of HAYA Therapeutics.
  • Over 25 years of experience in health technology and healthcare sectors.
  • Will oversee business development, strategic collaborations, HR, finance, IT, and quality assurance.
  • Aims to drive scalable growth and international expansion for HAYA.

Source: Business Wire

Notable Quotes

  • “Eric brings a wealth of biopharma expertise to oversee core operational functions including business development and strategic collaborations, human resources, finance, IT, communications and quality assurance. His career spans scientific and entrepreneurial roles in the pharmaceutical industry, biotechnology, medical device companies and significant contributions in the non-profit arena, which will help as we bring our first program, HTX-001 into the clinic. We welcome Eric to the HAYA family.” — Samir Ounzain, Ph.D., Co-founder and CEO at HAYA Therapeutics
  • “I thrive on driving cultural shifts, fostering innovation, and boosting team performance to deliver successful portfolios. At HAYA I aim to translate complex research into clear priorities and decisions at the C-level keeping the bigger picture – patients and the pipeline – in mind.” — Eric Adam, Ph.D., Chief Operating Officer at HAYA Therapeutics

SoHC's Take

The appointment of Eric Adam as Chief Operating Officer at HAYA Therapeutics signifies a strategic move to enhance the company’s operational capabilities and streamline its growth trajectory. With his extensive background in biopharma and proven track record in driving innovation and strategic alliances, Dr. Adam is well-positioned to support HAYA’s mission of developing groundbreaking RNA-targeted therapeutics. His experience with global pharmaceutical giants and non-profit initiatives will be invaluable as HAYA advances its therapeutic pipeline and expands its international presence. This leadership change underscores HAYA’s commitment to pioneering advancements in precision medicine, particularly in targeting long non-coding RNAs for disease treatment.

More To Explore

Total
0
Share